Recent News

• 06.09.2026 - Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
• 05.20.2026 - Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
• 05.11.2026 - Cellectis Reports Financial Results for the First Quarter 2026
• 05.04.2026 - Cellectis to Report First Quarter Financial Results on May 11, 2026

Recent Filings

• 05.21.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.21.2026 - EX-99.1 EX-99.1
• 05.20.2026 - EX-99.1 EX-99.1
• 05.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.12.2026 - EX-99.1 EX-99.1
• 05.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.11.2026 - EX-99.1 EX-99.1
• 05.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.11.2026 - EX-99.1 EX-99.1